SUPPORTING INFORMATION FOR

Design, synthesis and biological evaluation of arylsulfonamides as ADAMTS7 inhibitors

Doretta Cuffaro,^{1,¶} Tina Burkhard,^{2,¶} Bianca Laura Bernardoni,¹ Riccardo Di Leo,¹ Xiaohan Zhang,³ Salvatore Galati,¹ Tiziano Tuccinardi,¹ Marco Macchia,¹ Armando Rossello,¹ Salvatore Santamaria,^{2,#,*} Rens de Groot, ^{3,#,*} and Elisa Nuti^{1,#,*}

¹ Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy

² Department of Biochemical and Physiological Sciences, School of Biosciences, Faculty of Health and Medical Sciences, Edward Jenner Building, University of Surrey, Guildford GU2 7XH, UK

³ Institute of Cardiovascular Science, University College London, 51 Chenies Mews, London WC1E 6HX, UK.

*Correspondence: Salvatore Santamaria, e-mail: <u>s.santamaria@surrey.ac.uk;</u> Rens de Groot, e-mail: <u>R.deGroot@ucl.ac.uk;</u> Elisa Nuti: e-mail: <u>elisa.nuti@unipi.it</u>

[¶] D.C. and T.B. contributed equally to this work.

[#] E.N. and RdG and S.S. contributed equally to this work.

Table of Contents

I.	Representative NMR spectra of final compounds (1, 2, 3, 3a-g, and 4)	S2
II.	Representative HRMS spectra of final compounds (1, 2, 3, 3a-g, and 4)	S13
III.	Representative NMR spectra of intermediate compounds	S20
IV.	Figure S1	S43
V.	Figure S2	S43

S1

I. Representative NMR spectra of final compounds (1, 2, 3, 3a-g, and 4)

Compound 1: ¹H NMR (400 MHz, DMSO-*d*₆)



Compound 2: ¹H NMR (400 MHz, CD₃OD)



Compound 2: ¹³C NMR (100 MHz, CD₃OD)



Compound **3**: ¹H NMR (400 MHz, CD₃OD).



Compound **3**: ¹³C NMR (100 MHz, CD₃OD).



Compound **3a**: ¹H NMR (400 MHz, DMSO-*d*₆).



Compound **3a**: 13 C NMR (100 MHz, DMSO- d_6).



Compound **3b**: ¹H NMR (400 MHz, CDCl₃).



Compound **3b**: ¹³C NMR (100 MHz, CDCl₃).



Compound **3c**: ¹H NMR (400 MHz, CD₃OD).



Compound **3c**: ¹³C NMR (100 MHz, CD₃OD).



Compound **3d**: ¹H NMR (400 MHz, DMSO-*d*₆).



Compound **3d**: 13 C NMR (100 MHz, DMSO- d_6).



Compound **3e**: ¹H NMR (400 MHz, DMSO-*d*₆).



Compound **3e**: ¹³C NMR (100 MHz, CD₃OD).



Compound **3f**: ¹H NMR (400 MHz, DMSO-*d*₆).



Compound **3f**: 13 C NMR (100 MHz, DMSO- d_6).



Compound **3g**: ¹H NMR (400 MHz, DMSO-*d*₆).



Compound 4: ¹H NMR (400 MHz, CD₃OD).



Compound 4: ¹³C NMR (100 MHz, CD₃OD).



II. Representative HRMS spectra of final compounds (1, 2, 3, 3a-g, and 4)



HRMS spectrum of compound 1

HRMS spectrum of compound 2



HRMS spectrum of compound 3













HRMS spectrum of compound 3c







HRMS spectrum of compound 3e



HRMS spectrum of compound 3f





HRMS spectrum of compound 3g



S18

HRMS spectrum of compound 4



III. Representative NMR spectra of intermediate compounds

Scheme 1: Synthesis of final compound 1



Compound 6: ¹H NMR (400 MHz, DMSO).



Compound 6: ¹H-¹H COSY NMR (400 MHz, DMSO).



Compound 7: ¹H NMR (400 MHz, CDCl₃).



Compound 8: ¹H NMR (400 MHz, DMSO).



Compound 9: ¹H NMR (400 MHz, CDCl₃).



Compound **10**: ¹H NMR (400 MHz, DMSO).



Scheme 2: Synthesis of final compounds 2,4



Compound **11**: ¹H NMR (400 MHz, CDCl₃).



Compound **12**: ¹H NMR (400 MHz, CDCl₃).



Compound 13: ¹H NMR (400 MHz, CDCl₃).



Compound 14: ¹H NMR (400 MHz, DMSO).



Compound 15: ¹H NMR (400 MHz, MeOD).



Compound 16: ¹H NMR (400 MHz, CDCl₃).



Compound **16**: ¹H-¹H COSY NMR (400 MHz, CDCl₃).



Compound 17: ¹H NMR (400 MHz, CDCl₃).



Compound 18: ¹H NMR (400 MHz, DMSO).



Compound 19: ¹H NMR (400 MHz, MeOD).



Scheme 3: Synthesis of final compound 3



Compound **20**: ¹H NMR (400 MHz, DMSO).



Compound **21**: ¹H NMR (400 MHz, CDCl₃).





S30

Scheme 4: Synthesis of final compounds 3a-g



Compound 24: ¹H NMR (400 MHz, CDCl₃).



S31

Compound **25**: ¹H NMR (400 MHz, CDCl₃).



Compound **26**: ¹H NMR (400 MHz, CDCl₃).



Compound 27: ¹H NMR (400 MHz, CDCl₃).



Compound 27: ¹³C NMR (400 MHz, CDCl₃).



Compound 28: ¹H NMR (400 MHz, CDCl₃).



Compound **29**: ¹H NMR (400 MHz, CDCl₃).



S34

Compound **30:** ¹H NMR (400 MHz, CDCl₃).



Compound **31a:** ¹H NMR (400 MHz, CDCl₃).



Compound **31b:** ¹H NMR (400 MHz, CDCl₃).



Compound **31c:** ¹H NMR (400 MHz, CDCl₃).



Compound **31d:** ¹H NMR (400 MHz, CDCl₃).



Compound **31e:** ¹H NMR (400 MHz, CDCl₃).



Compound **31f:** ¹H NMR (400 MHz, CDCl₃).



Compound **31g:** ¹H NMR (400 MHz, CDCl₃).



Compound **32a:** ¹H NMR (400 MHz, CDCl₃).



Compound **32b:** ¹H NMR (400 MHz, CDCl₃).



Compound **32c:** ¹H NMR (400 MHz, CDCl₃).



Compound **32d:** ¹H NMR (400 MHz, CDCl₃).



Compound **32e:** ¹H NMR (400 MHz, CDCl₃).



Compound **32f:** ¹H NMR (400 MHz, DMSO).



Compound **32g:** ¹H NMR (400 MHz, DMSO).





Figure S1. The plot shows the RMSD of **3a** and protein heavy atoms for the ADAMTS5-**3a** (A) and ADAMTS7-**3a** (B) complexes during the MD simulations.



Figure S2. Original Western Blot for the image shown in Figure 2 in the main text. In the latter, the last lane of the original image as shown here was cropped out as it related to a different experiment.